Möchten Sie immer auf dem neuesten Stand bleiben?

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time...

MILAN, April 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) focused on large gene...

PRISM MarketView Features Exclusive Q&A with SBC Medical CEO Yoshiyuki Aikawa on Growth Strategy, U.S. Expansion, and Improving Unit Economics

Exton, PA, March 31, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing...

The new ZEISS Crossbeam 750 focused ion beam-scanning electron microscope (FIB-SEM) is optimized for demanding sample preparation.

ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today...

WHITE PLAINS, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer and leader in bio-interventional ophthalmic surgery (BIOS), today announced the introduction and US controlled release...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...